Skip To Main Content

Nexviazyme®
(avalglucosidase alfa)
Six Minute Walk Test (6MWT)

Help improve their mobility - move to Nexviazyme1

Patients treated with NEXVIAZYME walked 30 metres further in the 6MWT vs patients treated with MYOZYME (alglucosidase alfa) at Week 49 (nominal P=0.04).‡1

6MWT, 6 minute walk test; CI, confidence interval; LS, least squares; SD, standard deviation; SE, standard error.

  1. Nexviazyme Australian Approved Product Information.

Please review full Nexviazyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.

â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

 

 

Please review full Myozyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.

Life Saving Drugs Program - Pompe disease - Guidelines are available at www.health.gov.au/resources/publications/lsdp-pompe-guidelines.

Nexviazyme® and Myozyme​​​​​​​® are registered trademarks of Sanofi.

MAT-AU-2201156 - 2.0 - 05/2024